This includes utilization of Medistem’s newly discovered Endometrial Regenerative Cell population and Orcrist’s recently licensed HYC750 technology.
Gary Voncina, CEO of Orcrist Bio, said: “The potential for collaboration around Orcrist’s stem cell mobilization technology and Medistem’s core intellectual property could lead to ground-breaking advancements in the commercialization of stem cell products.”